Impact of a pharmacotherapeutic programme on control and safety of long-term anticoagulation treatment: A controlled follow-up study in spain

Drug Safety

Volumn 34, Issue 6, 2011, Pages 489-500

  Duran Parrondo, Carmen ^a   Vazquez Lago, Juan M ^b,c   Campos Lopez, Ana M ^d   Figueiras, Adolfo ^c,e  

^a Galician Health Service   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^d Pontevedra Primary Care Authority   (Spain)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Anticoagulants; Coagulation monitoring; Haemorrhage; Patient education; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CONTROL; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SERVICE; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACIST; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF CONTROL; SPAIN; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; COHORT STUDIES; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LONG-TERM CARE; MALE; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; SPAIN; THROMBOEMBOLISM;

EID: 79956150218     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11588520-000000000-00000     Document Type: Article

References (52)

1. Van Walraven C, Austin PC, Oake N, et al. The influence of hospitalization on oral anticoagulation control: a popula-tion-based study. Thromb Res 2007; 119: 705-14 (Pubitemid 46454330)
2. Hirsch J, Dalen JE, Anderson DR, et al. Oral anticoagulants mechanisms of action, clinical effectiveness and optimal therapeutic range. Chest 2001; 119 Suppl.: 8-21S
3. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 1993; 118 (7): 511-20 (Pubitemid 23085793)
4. Ansell J, Hirsch J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 Suppl.: 204-33S
5. Poller L, Keown M, Chauhan N, et al. Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. BMJ 2003; 327: 30-2 (Pubitemid 36801893)
6. Garcia D, Regan S, Crowther M, et al. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005; 127: 2049-56
7. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheu-matic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333: 5-10
8. Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Antico-agulation Clinics. Ann Intern Med 1996; 124: 970-9
9. Van der Meer FJ, Rosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulation therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-62 (Pubitemid 23205854)
10. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8 (Pubitemid 26267872)
11. Wittkowsky AK, Nutescu EA, Blackburn J, et al. Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest 2006; 130: 1385-9 (Pubitemid 44786730)
12. Wofford JL, Wells MD, Singh S. Best strategies for patient education about anticoagulation with warfarin: a system-atic review. BMC Health Serv Res 2008; 8: 40-7
13. Khan TI, Kamali F, Kesteven P, et al. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of antico-agulation. Br J Haematol 2004; 126: 557-64 (Pubitemid 39093099)
14. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333: 11-7
15. Tangelder MJD, Algra A, Lawson JA, et al. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. J Vasc Surg 2001; 33 (3): 522-7 (Pubitemid 32215601)
16. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325 (7372): 1073-5 (Pubitemid 35351801)
17. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996; 27 (6): 1349-55 (Pubitemid 26153278)
18. Biscup-Horm PJ, Streiff MB, Ulbrich TM, et al. Impact of an inpatient anticoagulation management service on clinical outcomes. Ann Pharmacother 2008; 42: 777-82 (Pubitemid 351778085)
19. Van den Bemt PMLA, Beinema M, Van Roon EN, et al. Initiation of oral anticoagulant therapy in orthopedic and surgical patients: an algorithm compared with routine dosing. Eur J Clin Pharmacol 2002; 58: 203-8 (Pubitemid 34639575)
20. Chan FWH, Wong RSM, Lau WH, et al. Management of Chinese patients on warfarin therapy in two models of anticoagulation service: a prospective randomized trial. Br J Clin Pharmacol 2006; 62: 601-9
21. Marco F, Sedano C, Bermudez A, et al. A prospective controlled study of a computer-assisted acenocoumarol dosage program. Pathophysiol Haemost Thromb 2003; 33: 59-63 (Pubitemid 37449279)
22. Wilt VM, Gums JG, Ahmed OI, et al. Outcome analysis of a pharmacist-managed anticoagulation clinic. Pharmaco-therapy 1995; 15: 732-5
23. Chau T, Rotbard M, King S, et al. Implementation and evaluation of a warfarin dosing service for rehabilitation medicine: report from a pilot project. Can J Hosp Pharm 2006; 59: 136-47 (Pubitemid 46838462)
24. Ellis RF, Stephens MA, Sharp GB. Evaluation of a pharmacy-managed warfarin monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm 1992; 49: 387-94
25. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127: 1515-22 (Pubitemid 46218774)
26. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999; 281: 145-50 (Pubitemid 29045346)
27. Colombet I, Bura-Riviere A, Chatila R, et al., for the PHRC-OAT Study Group. Personalized versus non-personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis. BMC Health Serv Res 2004; 4: 27-34
28. Bungard TJ, Gardner L, Archer SL, et al. Evaluation of a pharmacist-managed anticoagulation clinic: improving patient care. Open Med 2009; 3 (1): 16-21
29. Aribas Mir L. Atencion al paciente con anticoagulacion. Guia de actuacion en Atencion Primaria. Barcelona: SEMFyC, 1998: 452-5
30. Carter B, Helling D. Ambulatory care pharmacy services: has the agenda changed? Ann Pharmacother 2000; 34: 772-87 (Pubitemid 30395777)
31. Chiquette E, Amato MG, Bussey HI. Comparison of ananticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-7 (Pubitemid 28371187)
32. Poon IO, Lal L, Brown EN, et al. The impact of pharmacistmanaged oral anticoagulation therapy in older veterans. J Clin Pharm Ther 2007; 32: 21-9 (Pubitemid 46213938)
33. Chamberlain MA, Sageser NA, Ruiz D. Comparison of anticoagulation clinic patient outcomes with outcomes from traditional care in a family medicine clinic. J Am Board Fam Pract 2001; 14 (1): 16-21 (Pubitemid 33605759)
34. Brull-Sabate JM, Gonzalez-Manero AF. Control del tratamiento anticoagulante oral en el Servicio Extremeno de Salud. Guia clinica, puncion capilar y protocolos de actuacion. Servicio Extremeno de Salud 2007; 1: 1-126
35. Complexo Hospitalario Universitario de Santiago de Compostela Anticoagulacion oral. Boletin de informacion ter-apeutica 2002:1; 33-6
36. Fustero Fernandes MV, Barcena Caamano M, Eito Arnal A, et al. Evaluacion del circuito y los resultados de la an-ticoagulacion oral en el medio rural: comparacion del me-todo habitual con un coagulometro portatil. Revista de la SEMG 2004; 69: 614-21
37. Haemostasis and Thrombosis Task Force for the British Committee for Standards in Haematology. Guidelines on oral anticoagulation. 3rd ed. Br J Haematol 1998; 101: 374-87
38. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat 1982; 10: 1100-20
39. Therneau TM, Hamilton SA. rhDNase as an example of recurrent event analysis. Stat Med 1997; 16: 2029-47 (Pubitemid 27421282)
40. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. JAMA 1989; 84: 1074-8
41. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989; 129: 125-37 (Pubitemid 19030705)
42. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-9 (Pubitemid 19077878)
43. Jackson SL, Peterson GM, Vial JH, et al. Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. J Intern Med 2004; 256: 137-44 (Pubitemid 38998260)
44. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8-21S
45. Saokaew S, Permsuwan U, Chaiyakunapruk N, et al. Effectiveness of pharmacist-participated warfarin therapy management: a systematic review and meta-analysis. J Thromb Haemost 2010; 8 (11): 2418-27
46. Whitley HP, Dermo JD, Chumney ECG, et al. Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag 2007; 3 (3): 499-504 (Pubitemid 47214991)
47. Lee VWY, You JHS, Lee KKC, et al. Factors affecting the maintenance stable warfarin dosage in Hong Kong Chinese patients. J Thromb Thrombolysis 2005; 20: 33-8
48. Pamboukian SV, Nisar I, Patel S, et al. Factors associated with non-adherence to therapy with warfarin in a popula-tion of chronic heart failure patients. Clin Cardiol 2008; 31: 30-4
49. Wilson SJA, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003; 169: 293-8 (Pubitemid 37047057)
50. WHO Committee of Experts on obesity. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. WHO technical report series, 894. Geneva: WHO, 2000
51. Davidson BL, Buller HR, Decousus H, et al. Effect of obesity on outcomes after fondaparinux, enoxaparin, or hep-arin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost 2007; 5: 1191-4 (Pubitemid 46902121)
52. Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obe-sity, and the risk of recurrent venous thromboembolism. Arch Intern Med 2008; 168: 1678-83